Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06445803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

StatusRecruiting
PhasePhase 1
SponsorRong Tao
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.
Trial Details
NCT Number NCT06445803
Lead Sponsor Rong Tao
Collaborators: Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Conditions
(from sponsor)		 Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Related terms Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov